Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.
10.1097/CM9.0000000000003705
- Author:
Shengbai XUE
1
;
Weihua JIANG
2
;
Jingyu MA
1
;
Haiyan XU
1
;
Yanling WANG
1
;
Wenxin LU
1
;
Daiyuan SHENTU
1
;
Jiujie CUI
1
;
Maolan LI
3
;
Liwei WANG
1
Author Information
1. Department of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
2. Department of Oncology, Punan Hospital in Pudong New District, Shanghai 200125, China.
3. Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
- Publication Type:Review
- Keywords:
Adoptive cell therapy;
Cholangiocarcinoma;
Epidermal growth factor receptor;
Immune checkpoint inhibitors;
Immunotherapy;
Programmed cell death 1/ programmed cell death 1 ligand 1;
Targeted therapy;
Vascular endothelial growth factor
- MeSH:
Humans;
Cholangiocarcinoma/drug therapy*;
Immunotherapy/methods*;
Bile Duct Neoplasms/drug therapy*;
Molecular Targeted Therapy/methods*
- From:
Chinese Medical Journal
2025;138(16):1904-1926
- CountryChina
- Language:English
-
Abstract:
Cholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA. The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.
